Statement by Mr. Nicolas Sarkozy, President of the Republic, on efforts in favor of research, in Paris on June 5, 2009.

France Nicolas Sarkozy · President of France

5 June 2009 · Statement on efforts in favour of research · Paris, France

Context
Sarkozy addressed international pharmaceutical research laboratory heads and G5 leaders in Paris on June 5, 2009, to promote France's research reforms and partnerships.
Main themes
Research and innovation investment, knowledge economy, pharmaceutical industry partnership, Alzheimer's disease and neuroscience, French research reform, public-private research collaboration, higher education funding, French competitiveness, G5 pharmaceutical companies, biomedical research restructuring
Duration
~20 min
65th percentile
Words
2,372
65th percentile
Sentences
169
85th percentile
Readability
52
69th percentile
Grade
9.5
15th percentile
Syntax
2.65
9th percentile
Vocabulary
2.16
39th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 34%33%
  • Institutional 27%27%
  • Social 22%22%
  • Ceremonial 14%14%
  • Geopolitical 2%2%
  • Technological 1%1%
  • Environmental 0%0%
  • Not in focus 2%

169 sentences in 95 paragraphs

Ladies Ministers,

Ladies and Gentlemen Presidents of International Research Laboratories,

Gentlemen Presidents and General Directors of the G5,

Mr. President of INSERM, dear André Syrota,

Mr. General Administrator of CEA, dear Bernard Bigot,

Madam President of CNRS, dear Catherine Bréchignac,

Gentlemen Professors,

Ladies and Gentlemen,

The world will never be the same as it was before the crisis we are going through. Growth will no longer rely solely on the production and consumption of goods and services, which become obsolete ever more quickly as knowledge progresses. Growth will now depend on the education of young people, on research, and on innovation.

The states that will meet the challenges of tomorrow are those that prioritize research, innovation, and education. This is the knowledge economy. What I am saying is not original, but I believe it deeply.

We have decided to invest massively in research and higher education because the engine of growth lies in these areas. One billion euros is added each year for five years to the budget of universities, and there are 800 million euros that, each year for five years, will supplement the research budget.

But adding resources is necessary, but it is not enough!

We needed to reorganize ourselves!

We needed to reform deeply.

We needed to restructure our public research, which has so many talents and whose potential is very great.

We had to professionalize our valorization structures. We still need to do that.

We need to learn to cooperate better with private research.

A great nation must attract or retain the best researchers and the most dynamic companies.

If I wanted to meet with you today, you, the heads of Research and Development of International Pharmaceutical Research Laboratories, it is because I appreciate your pragmatism, your boldness, your entrepreneurial spirit.

But I owe you the truth. I invited you to tell you where we stand.

To convince you that France is changing. To invite you to look at this France with a new and confident perspective. I invited you to propose that you be partners in facing the challenges ahead.

I wanted you to meet great doctors, great French researchers all ready to work with you!

I wanted to associate with this day the five major players in the French, European, and global pharmaceutical industry that make up the G5: Ipsen, LFB, Pierre Fabre, Sanofi Aventis, and Servier.

Inheritor of a long tradition, the G5 makes research a priority. It makes strengthening its competitiveness an imperative, and maintaining its decision-making centers in France a principle.

With 11% of the global pharmaceutical industry's R&D budget, the G5 is a driver for French economic growth. With 25,000 people dedicated to research and development, including 12,000 in France, the G5 contributes to employment, and for us, this is a central issue.

That is why a day like today could not be conceived without you, the presidents and general directors of the G5!

I commit today to ensuring that the health industries become a major axis of France's competitiveness. The socio-economic stakes are enormous.

A European body recently estimated the cost of brain diseases in Europe at 390 billion euros per year, including 55 billion euros per year for Alzheimer's disease alone!

On February 1, 2008, I announced the launch of the French Alzheimer Plan: 1.6 billion euros over five years. The Plan provides for the creation of a Scientific Cooperation Foundation to which several companies from the G5 and the LIR immediately associated themselves.

You are gathered here to talk about diseases of the nervous system, particularly Alzheimer’s. This is an unprecedented political, societal, economic, and health challenge.

We wanted to introduce you to the best French research teams in the field of neuroscience.

We wanted to introduce you to national platforms, such as Neurospin, MIRCen, and the Brain and Spine Institute.

We wanted to introduce you to the Research Tax Credit. Did you know that France now has the most attractive tax system in the world? But, in addition to the pleasure I have in welcoming you, I must tell you that I have another reason for satisfaction today...

You are invited, not by one of the multiple organizations or agencies that made up the fragmented landscape of French biomedical research less than two years ago, dear Valérie.

No, you are invited today at the initiative of INSERM, and of André Syrota, its president, by the Alliance of Life and Health Sciences.

The Alliance now brings together all public actors in French biomedical research: INSERM, CNRS, CEA, INRA, and the Pasteur Institute. This was one of the recommendations of the Zerhouni report. I cannot thank you enough, Mr. Zerhouni. It is done, you recommended it to us, it is done, France is changing, now it does what it says.

Organized into 10 thematic multi-agency institutes without walls - including the Institute of Neurosciences - the Alliance aims to play, like the NIH in the USA, a central role in the animation, programming, and funding of project-based research by the National Research Agency.

Mr. Zehrouni, I tell you, we will implement not just some of your recommendations, but all, you understand, all the recommendations of your report. Because all are vital for the renewal of biomedical research.

Allow me once again to thank you, dear Elias, for your contribution.

You understand that it is not our intention to "dismantle" research organizations. It is simply a reminder that "no one can be both judge and party."

No one can be the one who decides on a direction, who finances it, who implements it, and who ultimately evaluates it.

This is no longer done anywhere in the world.

We are determined to clearly distinguish from now on:

- the strategic coordination missions of biomedical research, entrusted to the Alliance,

- the evaluation missions of research, entrusted to the Agency for the Evaluation of Research and Higher Education, AERES,

- and the research operator missions, also entrusted to universities.

And you see this incredible thing: France is capable of changing, of reforming, without drama.

To make research the engine of growth, we needed to restructure our public research. We have done it.

We needed to give autonomy to our major research universities so that these universities could have the freedom to decide the best scientific strategies with their partners. We have done it.

Have you seen us retreat?

It is not very original. It is done.

In all the major industrialized countries in the world, universities have been autonomous for years.

In all the major industrialized countries in the world, universities have been autonomous for years.

Well, French universities are now autonomous.

I now tell our researchers in whom I place so much hope: we need to learn to cooperate better with private research.

And to cooperate, we need to know each other better, to understand each other better.

I would also like to be more attentive to you, the leaders of major pharmaceutical laboratories.

I want to understand you better, and do you know why I want to understand you better? Because I want to help you better, because it is crucial for the future of our country and our growth.

Public research and private research are not exclusive of each other. They are complementary.

Quality public research attracts industry. Strong industries, well established in French competitiveness clusters, in turn become active partners for public research. However, the pharmaceutical industry will face many challenges in the coming years.

And nothing is guaranteed! I know that well.

There is not one side public research, with its legendary burdens, and on the other side the prosperous and dynamic pharmaceutical industry. The pharmaceutical industry also faces difficulties, even a certain loss of productivity. This decline is evidenced by the reduction in the number of new drugs launched on the market, particularly from Europe. This is not a reproach to anyone; it is simply looking at reality as it is.

This decline, you tell me, is not quantitative. It is qualitative, due to a lack of alignment with new needs.

In fact, for many common diseases, such as diabetes or hypertension, needs are already met by existing treatments at relatively modest costs.

The new needs lie elsewhere: cancers, neurological diseases, Alzheimer’s disease, emerging diseases, AIDS, rare diseases. Since it takes 10 years to develop a new molecule, I conclude that the drugs being tested today were designed in the last century. In the 20th century. We are in the 21st century.

Moreover, in the name of the precautionary principle, every new product must prove its safety, leading to longer clinical trials and therefore slower market penetration.

The consequences are well known.

Fewer new molecules are reaching the market: you speak of "attrition," I believe...

Research expenditures have become so significant that they make the companies' profits uncertain. Revenues are rising slowly, profits are lower, and protections are shorter.

Delisting looms as soon as a generic appears in the same class of drugs.

Given the increasing complexity of therapeutic innovation, closer cooperation between public and private research is needed. It is possible. We have managed to do it for the aerospace industry, for civil nuclear power. Why not do it under the same conditions for the pharmaceutical industry?

Through your innovation potential, you have a double economic impact: on growth and on the improvement of population health...

Future pathways exist: you will, as you told me, focus your research on diseases for which treatments are nonexistent or unsatisfactory.

Building on computing and individual genomics, you will move from collective medicine to personalized medicine.

You will soon be able to increase the tolerance and effectiveness of treatments by identifying patient groups that respond to treatments. This is already the case with chemotherapy for several cancers.

Finally, with new classes of drugs derived from biotechnology and with adult stem cells, you will decisively contribute to the rise of regenerative and reparative medicine.

From these drugs of tomorrow, you expect fewer surprises, fewer side effects, and a longer market life. We need to jointly discuss the future of the pharmaceutical industry in France.

Responses must be developed together by the Government and the companies.

I wish for the Strategic Council of Health Industries to meet in the coming days to decide on concrete measures.

So, after the commitments I have made before you, allow me to make a double wish!

That you succeed in your research projects, and that this day also sees the emergence of concrete projects between you!

For Alzheimer’s or for any other neurological disease!

For joint research programs, common clinical trials, projects for mobility between universities and industry on one of our major platforms or in our Hospital-University Institutes, proposed by the Marescaux Commission to identify excellence in biomedical research.

In a word, I would like you to establish privileged relationships with France. And that the pessimists do not tell me that health research will now be driven by the needs of the economy.

Let it not be said that I want to reduce biomedical research to its only applications. Let it not be said that I want to subject our universities to the laws of the market. That is not the point!

I know well that the great discoveries of science are often serendipitous. That they were not inscribed in a pre-designed research program. But precisely, by offering autonomy to universities, we have liberated energies, loosened the shackles of conformity. We have put an end to the demonization that the industrial world has long faced from some.

I no longer want to read, under the pen of a renowned French economic journalist, "that in France, to be a good researcher, one must be poor and stubbornly refuse to talk to industrialists." That is what was written in old France and what can no longer be written today.

On the contrary, I want to enable researchers to fully participate in the knowledge economy.

I want to make our universities places of cross-fertilization with businesses, true territorial integrators of education, research, and its applications.

Innovation and valorization need proximity, flexibility, and responsiveness. Do you understand that I want to help you? That the government is fully mobilized. What would be the point of having the best social protection system if, at the same time, we discouraged researchers and laboratories from finding molecules and new treatments? What is the use of being the country with the most pleasant quality of life in the world if one can no longer work there? If one cannot think there? If one can no longer create? If one can no longer live their passion? And we are in the process of changing things. I will not stop along the way. I want everyone to understand this clearly.

France has been changing for two years, and it will continue to change. And no stagnation, no conformism will stop us. Because the only thing that matters is the general interest. We are entering the knowledge economy; France cannot be a stranger to this economy. You are the expression of this knowledge. By targeting the health industries, I wanted to show, alongside Christine LAGARDE and Valérie PECRESSE, that the health industries and biomedical research are a strategic economic sector for us, just like energy, communication, automotive, or finance. It is strategic.

So, define among yourselves, define with the ministers what you need. For foreigners, set up new laboratories in France. You are welcome. For the French, stop thinking that by setting up new laboratories abroad, you will have the best conditions. That is false!

And for us, let us be more attentive to your requests, to your problems, to your difficulties. For you too, work together—have a different view of our universities that are changing. Have a different view of our public institutions that are filled with very high-quality men and women. Do you understand this well? France has a will and an ambition in your field; France will be the most welcoming country in the world.

If you agree, we will meet again every year, and each year will be an opportunity for you to check if I have done what I said. And I too, on my side, will check if you have done what I asked you to do.

Thank you all.